Everything in the media lately has been crypto this, inflation that… And that’s fair. Inflation is a big concern for the markets and crypto is the “sexy” thing right now.
But inflation is old news, even if the media says otherwise… So it’s time to shift our focus as the world shifts its stigmas. There’s a big change in how alternative medicine stocks are viewed, especially the big two: cannabis and psilocybin.
It wasn’t long ago that cannabis was a 100% illegal substance. Yes, that fight is still going on, but the narrative is different. When President Joe Biden took office it became a given that cannabis would be federalized. As of today, 36 states have legalized medical marijuana and only three have absolutely no public access to cannabis — legally anyway.
Source: National Conference of State Legislatures
And as we mentioned in the beginning of May, the House of Representatives passed a bill by a 3-to-1 margin to allow the cannabis industry to use the federal banking system.
Obviously, we’ve come a long way since 1970 with regards to cannabis… But what about our other alternative medicine stock?
While marijuana is used to treat a wide range of symptoms and diseases, primarily pain and seizures, psilocybin is being tested for a subject that is both uncomfortable for some and relatable for many…
Mental health is gradually seeing its own change in stigma. Per the National Institute of Mental Health, “nearly one in five U.S. adults live with a mental illness,” as of 2019, that number is about 51.5 million people… and that doesn’t include U.S. citizens under the age of 18 or outside of the U.S.
Source: National Institute of Mental Health
We can’t imagine that number has gone down in the last two years. But another part of that could be that people are more open about their mental health than ever before.
Just like alternative medicine, the stigma is reducing.
Are psychedelics the answer?
If you ask Wesana Health CEO and former professional hockey player Daniel Carcillo, the answer is an emphatic “yes.”
In an interview with CNBC, Carcilla opened up about his mental health struggle. As a result of a traumatic brain injury sustained during his hockey days, he’s battled chronic, severe depression. Standard treatments and even some various alternative medicines had no effect, and he found himself on the verge of suicide.
Then he discovered psilocybin-based treatments, and with the correct guidance, said within two weeks his symptoms lessened more and more.
From the article and Carcillo himself:
“‘Lots of amazingly destructive thought patterns disappeared in two weeks,’ he recalled — and today, he no longer suffers from anxiety and depression.”
That may be anecdotal evidence, but the growing amount of research into the topic supports his story.
And in that same interview, Shark Tank host Kevin O’Leary said the potential of the psilocybin market is greater than that of cannabis…
One of the most prominent alternative medicine stocks is MindMed Inc. (Nasdaq: MNMD). It’s in the Fortune Research Pro portfolio, and one we’re watching as research into psychedelics continues.
Speaking of hockey and mental illness, one of the biggest issues in sports to come up in the past decade was American football. After it became apparent that NFL players dealt with lifelong mental health issues due to micro-concussions sustained in the contact sport, the league changed its rules.
But concussions are still going to happen, and there are still hundreds of retired players who could end up dealing with these issues.
And we know… Most of us are not professional football players and maybe have never even had a concussion, so why does this matter on the large scale?
Because the symptoms associated with these brain injuries are akin to severe, chronic anxiety and depression. In 2019, the World Health Organization (WHO) estimated that 264 million people were affected by anxiety and depressive disorders.
Traditional treatments do work for most, but it’s no secret that they come with a range of potentially severe side effects.
So what if an alternative medicine came out with more minimal side effects, and just as much success?
A study done, represented in the chart below, shows that patients undergoing psilocybin treatment experienced a reduction in the severity of their depression that was largely sustained for three months. And 67% of patients went into complete remission of their depression.
Source: The Lancet Psychiatry
Those numbers are very encouraging… And if the trend continues, this could redefine how mental health is treated.
There’s a social shift going on in mental healthcare, and it could bust the door wide open for alternative medicine stocks.
Needless to say, this is a sector worth keeping an eye on.
All the best,
P.S. Wall Street legend Chuck Hughes is embarking on a journey to change lives this summer…
Handing over three secrets he’s never shared with anyone before…
And kicking off a select group of traders with a special $50,000 challenge account.
If anyone wants to join Chuck on this never seen before challenge…